Close Menu

NEW YORK (GenomeWeb) – After launching the tissue-directed TruSight Oncology 500 panel late last year, Illumina has now cemented a partnership that, along with potential others, will validate the firm's comprehensive sequencing assay for an eventual liquid biopsy application.

Researchers from the Molecular Characterization Laboratory at the National Cancer Institute's Frederick National Laboratory said last month that they plan to use TSO 500 to support multiple clinical studies, assessing liquid biopsy samples from up to 7,000 subjects.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

An initial analysis suggests the novel coronavirus from Wuhan that is sickening people might come from snakes, a team of virologists writes at the Conversation.

DNA testing confirms captured Chicago coyote same as the one that bit a boy near a nature museum, the Chicago Tribune reports.

An analysis of Tibetan ice cores uncovers more than two dozen previously unknown virus groups, LiveScience reports.

In Nature this week: genomic analysis of four children buried in Cameroon approximately 3,000 and 8,000 years ago, and more.